Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $117.0 million.

  • Tarsus Pharmaceuticals' Total Current Liabilities rose 7770.39% to $117.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.0 million, marking a year-over-year increase of 7770.39%. This contributed to the annual value of $80.6 million for FY2024, which is 11824.78% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Total Current Liabilities is $117.0 million, which was up 7770.39% from $90.3 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Total Current Liabilities registered a high of $117.0 million during Q3 2025, and its lowest value of $10.1 million during Q1 2021.
  • Its 5-year average for Total Current Liabilities is $37.8 million, with a median of $15.4 million in 2022.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Total Current Liabilities skyrocketed by 511.5% in 2023, and later surged by 24927.87% in 2024.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Total Current Liabilities stood at $11.5 million in 2021, then skyrocketed by 34.42% to $15.4 million in 2022, then skyrocketed by 139.39% to $36.9 million in 2023, then skyrocketed by 118.25% to $80.6 million in 2024, then surged by 45.2% to $117.0 million in 2025.
  • Its Total Current Liabilities stands at $117.0 million for Q3 2025, versus $90.3 million for Q2 2025 and $86.3 million for Q1 2025.